Healthline

Non-small Cell Lung Cancer

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Business Wire

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation ...

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma ...
ascopubs.org

Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSé Program.

A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Phase I evaluation of the PI3 kinase (PI3K) inhibitor ...
FiercePharma

FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of sk

First and Only Personalized Medicine Shown to Help People With BRAF V600E Mutation-Positive Metastatic Melanoma, Found in Half of Melanoma Patients, Live Longer Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
Business Wire

Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma

IMspire150 is a Phase III, multi-center, double-blind, placebo-controlled randomized study in people with previously untreated BRAF V600 mutation-positive metastatic or unresectable locally advanced ...
FierceBiotech

Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF m

Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a ...
MedPage Today

Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination

First-line immunotherapy for BRAF-positive melanoma, followed by targeted therapy at progression, led to a "clinically meaningful" survival benefit, a randomized trial showed. Combination ...